Fair Value Measurements - Narrative (Details) $ / shares in Units, $ in Thousands		3 Months Ended	9 Months Ended
	Apr. 15, 2025 USD ($) day $ / shares	Sep. 30, 2025 USD ($)	Sep. 30, 2026 USD ($) shares	Sep. 30, 2025 USD ($)	Dec. 31, 2025 USD ($) shares
Cash and Cash Equivalents [Line Items]
Financial liabilities			$ 0		$ 2,670
Purchase of warrants (in shares) | shares			0		666,515
Gross revenue					$ 1,570
GeneDx | Private Placement Warrants
Cash and Cash Equivalents [Line Items]
Change in fair value of financial liabilities		$ (900)	$ 1,100	$ 1,100
Fabric Genomics
Cash and Cash Equivalents [Line Items]
Change in fair value of financial liabilities			(1,600)	$ 3,400
Price per shares (in dollars per share) | $ / shares	$ 93.0318
Number of trading days | day	30
Fabric Genomics | First Milestone Payment
Cash and Cash Equivalents [Line Items]
Cash payment	$ 10,500
Gross revenue	$ 6,000		5,400		5,400
Gross margin (as a percent)	69.00%
Amount obtained by multiplying milestone payment	$ 7,000
Amount obtained by dividing the quotient of milestone payment	8,000
Fabric Genomics | Second Milestone Payment
Cash and Cash Equivalents [Line Items]
Cash payment	7,500
Gross revenue	$ 9,000		0		$ 1,600
Gross margin (as a percent)	69.00%
Amount obtained by multiplying milestone payment	$ 5,000
Amount obtained by dividing the quotient of milestone payment	$ 12,000
Public Warrants
Cash and Cash Equivalents [Line Items]
Purchase of warrants (in shares) | shares					457,323
Private Placement Warrants
Cash and Cash Equivalents [Line Items]
Purchase of warrants (in shares) | shares					209,192
Maximum
Cash and Cash Equivalents [Line Items]
Maturity, at amortized cost			41,800
Minimum
Cash and Cash Equivalents [Line Items]
Maturity, at amortized cost			$ 32,000